Table 2.
Seroresponse rate in the single and mixed vaccine regimen groups
| Single vaccine regimen | Mixed vaccine regimen | Seroresponse rate difference (95% CI) | ||
|---|---|---|---|---|
| Number of participants | 601 | 1238 | .. | |
| Number of participants with seroresponse* | 178 | 415 | .. | |
| Seroresponse rate (95% CI) | 29·6% (26·1–33·4) | 33·5% (30·9–36·2) | 3·9% (−0·7 to 8·3) | |
| Four-fold increase in IgA antibodies vs baseline titre of ≥20 IU/mL | ||||
| Number of participants | 18 | 28 | .. | |
| Percentage (95% CI) | 3·0% (1·8–4·6) | 2·3% (1·5–3·2) | .. | |
| IgA antibody titre of ≥20 IU/mL vs titre <20 IU/mL at baseline | ||||
| Number of participants | 160 | 387 | .. | |
| Percentage (95% CI) | 26·6% (23·2–30·3) | 31·3% (28·7–33·9) | .. | |
*
Seroresponse was defined as a four-fold increase in IgA antibody titres after the third vaccine dose when baseline titre was 20 IU/mL or more, or an IgA antibody titre of 20 IU/mL or more after the third vaccine dose when baseline titre was less than 20 IU/mL.